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AbstrAct
Objective To address clinical uncertainties about the 
effectiveness and safety of long-term antibiotic therapy for 
preventing recurrent urinary tract infections (UTIs) in older 
adults.
Design Systematic review andmeta-analysis of 
randomised trials.
Method We searched Medline, Embase, The Cumulative 
Index to Nursing and Allied Health Literature(CINAHL), 
and the Cochrane Register of Controlled Trials from 
inception to August 2016. Eligible studies compared 
long-term antibiotic therapy with non-antibiotic therapy 
or placebo in men or women aged over 65, or in 
postmenopausal women, with recurrent UTIs.
Results We did not identify any studies that included 
older men. Three randomised controlled trials compared 
long-term antibiotics with vaginal oestrogens (n=150), 
oral lactobacilli (n=238) and D-mannose powder (n=94) 
in postmenopausal women. Long-term antibiotics reduced 
the risk of UTI recurrence by 24% (three trials, n=482; 
pooled risk ratio (RR) 0.76; 95% CI 0.61 to 0.95, number 
needed to treat=8.5). There was no statistically significant 
increase in risk of adverse events (mild adverse events: 
pooled RR 1.52; 95% CI 0.76 to 3.03; serious adverse 
events: pooled RR 0.90, 95% CI 0.31 to 2.66). One trial 
showed 90% of urinary and faecal Escherichia coli isolates 
were resistant to trimethoprim–sulfamethoxazole after 
1 month of prophylaxis.
Conclusions Findings from three small trials with 
relatively short follow-up periods suggest long-term 
antibiotic therapy reduces the risk of recurrence in 
postmenopausal women with recurrent UTI. We did not 
identify any evidence to inform several clinically important 
scenarios including, benefits and harms in older men or 
frail care home residents, optimal duration of prophylaxis, 
recurrence rates once prophylaxis stops and effects on 
urinary antibiotic resistance.
InTroducTIon
Older men and women are commonly 
prescribed long-term antibiotics to 
prevent recurrent urinary tract infection 
(UTI).1 2 Antibiotic use is a key driver of anti-
biotic resistance.3 Therefore, antibiotic use 
must be justified by robust evidence, where 
the estimated benefit outweighs estimated 
harm.
UTIs, and consequently recurrent UTIs, 
are overdiagnosed in older people.4 5 There-
fore, antibiotic prophylaxis may actually 
be prescribed for symptoms that represent 
bladder dysfunction or localised vaginal symp-
toms rather than true UTI, and thus will not 
confer the intended benefit. Multimorbidity, 
frailty and polypharmacy are more common 
in older people and are contributory factors 
for potential harms such as those related to 
drug interactions. For example, older adults 
coprescribed renin–angiotensin system inhib-
itors and trimethoprim-containing antibiotics 
were shown to be at increased risk of hyper-
kalaemia-related hospitalisation6 and sudden 
death.7
Previous meta-analyses showed antibiotic 
prophylaxis conferred a relative risk reduc-
tion of 79% in the proportion of women 
experiencing a microbiologically confirmed 
UTI, compared with placebo.8 However, these 
analyses included data from mostly small 
Strengths and limitations of this study
 ► Recurrent urinary tract infection is one of the most 
common reasons for long-term antibiotic use in 
the frail elderly. We systematically reviewed trial 
evidence to address clinical uncertainties around 
this practice.
 ► We did not identify any trials in older men nor any 
trials in frail care home residents.
 ► We identified only three small European trials, with 
follow-up ranging from 6 to 15 months, in older 
women.
 ► Only one trial measured the impact of long-term 
antibiotics on antibiotic resistance.
 ► Trial evidence suggests long-term antibiotics reduce 
the risk of UTI recurrence in older women. Many 
clinical uncertainties remain unaddressed.
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trials of younger women without comorbidities. There is 
uncertainty around the generalisability of these findings 
to older adults.
There are several important clinical uncertainties 
relating to long-term antibiotic use in older adults with 
recurrent UTI, including effect on frequency of infec-
tive episodes, optimal duration of prophylaxis, adverse 
effects, risk of relapse following cessation of prophylaxis 
and effect on urinary antibiotic resistance. We therefore 
systematically reviewed randomised controlled trials 
comparing long-term antibiotic prophylaxis with placebo 
or non-antibiotic therapy for preventing further episodes 
of UTI in older people. Our main objective was to quan-
tify the benefits and harms of long-term antibiotics for 
older adults, to better inform patients and clinicians 
during clinical decision making.
MeThods
We conducted a systematic review following guidance from 
the Cochrane Handbook for Systematic Reviews of Interventions 
for conduct and PRISMA guidelines (see online supple-
mentary file PRISMA checklist) for reporting.9 The review 
protocol was prospectively registered on the International 
Prospective Register of Systematic Reviews (PROS-
PERO:%20http://www. crd. york. ac. uk/ PROSPERO/ 
display_ record. asp? ID= CRD42015016628; registration 
number: PROSPERO 2015:CRD42015016628).
data sources
We systematically searched Medline, Embase, CINAHL 
and the Cochrane Central Register of Controlled Trials 
from inception to March 2016 for English language 
randomised controlled trials. Our search strategy 
consisted of keywords and medical subject head-
ings terms for urinary tract infection and randomised 
trials (see online supplementary appendix 1).
One author (HA) conducted the first screening of 
potentially relevant records based on titles and abstracts, 
and two authors (HA and FD) independently performed 
the final selection of included trials based on full-text 
evaluation. Reference lists of included studies and 
relevant systematic reviews were screened for further 
potentially relevant studies. Disagreements between the 
two reviewers were resolved through discussion.
study selection
We included only randomised controlled trials published 
in full (ie, not abstracts) in English, comparing the effect 
of long-term antibiotics versus placebo or non-antibiotic 
interventions on the rate of UTI in older adults with 
recurrent UTI. We defined ‘long-term antibiotics’ as daily 
antibiotic dosing for at least 6 months, ‘older adults’ as 
women who were postmenopausal or over the age of 65 
and men aged over 65 and ‘recurrent UTI’ as self-re-
ported or clinically recorded history of two or more UTIs 
in 6 months or three or more in 12 months.
We included studies recruiting adults of all ages and 
screened relevant results to assess whether reported data 
allowed estimates of effect size in our specified popula-
tion of older adults. For data not presented in this format, 
we contacted authors if the study was published in the last 
10 years and if the mean or median age in any arm was 
greater than 50 years.
We excluded studies evaluating the effect of prophy-
lactic antibiotics in specific situations, for example, post 
catheterisation, postsurgery, in patients with spinal inju-
ries or in those with structural renal tract abnormalities.
outcome measures
Our primary outcome was the number of UTI recur-
rences per patient-year during the prophylaxis period, 
defined microbiologically (>100 000 colony-forming units 
of bacteria/mL of urine) and/or clinically (for example, 
dysuria, polyuria, loin pain, fever) or other measure of 
change in the frequency of UTI events during prophy-
laxis. We also aimed to assess the proportion of patients 
with severe (requiring withdrawal of treatment) and 
mild (not requiring withdrawal of treatment) adverse 
effects. Secondary outcomes included the proportion of 
patients who experienced at least one recurrence after 
the prophylaxis period, time to first recurrence, propor-
tion of patients with antibiotic resistant micro-organisms 
in future urine samples and quality of life.
data extraction and quality assessment
One reviewer (HA) extracted study characteristics (setting, 
participants, intervention, control, funding source) and 
outcome data from included trials. We contacted two 
authors for subgroup data on postmenopausal women. 
One author replied and provided relevant outcome data. 
Two reviewers (HA and SP) independently assessed the 
risk of bias of the included studies using the Cochrane 
Collaboration’s risk of bias tool.10 Disagreements were 
resolved through discussion. We used RevMan V.5.3 to 
meta-analyse the data and generate forest plots.
data synthesis and analysis
Outcomes measured in only one trial were reported 
narratively. Outcomes measured in more than one trial 
were synthesised quantitatively. We estimated between 
trial heterogeneity using the I2 statistic11 and used random 
effects meta-analyses to estimate pooled risk ratios and 
95% CIs.12 We undertook sensitivity analyses to examine 
treatment effects according to study quality and assessed 
the impact of including data from a potentially eligible 
trial where the study author did not reply to our request 
for data on older participants.
resulTs
From 6645 records, we identified 53 studies for full-
text review (see online supplementary appendix 
2). Four studies were eligible for inclusion.13–16 Two 
studies recruited only postmenopausal women.15 16 Two 
studies recruited women of all ages but the median 
age was >50 years.13 14 For these studies, we contacted 
authors requesting data for postmenopausal women, or 
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if menopausal status not ascertained, for women aged 
over 65. We received data from one author and hence 
included three trials consisting of 534 postmenopausal 
women in our review (table 1).14–16 We did not identify 
any studies that included older men.
Trial characteristics
Trials were conducted in community and outpatient 
settings in Israel, the Netherlands and Croatia. Only one 
trial included individuals with diabetes16 and only one 
trial included individuals with renal impairment.14 Inter-
vention arms consisted of 6 to 12 months of antibiotic 
therapy. Control arms consisted of non-antibiotic prophy-
laxis with vaginal oestrogen pessaries,15 oral lactobacilli 
capsules16 and D-mannose powder.14 One trial reported 
the number of UTI recurrences per patient year during 
the prophylaxis period.16 All trials reported the number 
of women experiencing a UTI during the prophylaxis 
period and frequency of adverse events. Only one trial 
assessed recurrence of UTI after the prophylaxis perio.16 
One trial assessed effect on urinary and faecal bacterial 
resistance.16
risk of bias
Figure 1 summarises the risk of bias assessment. Alloca-
tion and randomisation details were poorly reported 
in two trials.14 15 One trial was assessed as high risk for 
performance and detection bias; trial arms consisted of an 
oral antibiotic capsule or D-mannose powder diluted in 
200 mL water or no treatment with no use of placebo and 
did not report on blinding of outcome assessors.14 Only 
one trial reported a sample size calculation.14 Overall, 
one trial was judged to be low risk of bias16 and two trials 
unclear risk due to limited reporting of methods.14 15
effect of long-term antibiotics on recurrent uTI
Compared with a capsule of lactobacilli, prophylaxis with 
480 mg of trimethoprim–sulfamethoxazole for 12 months 
led to fewer microbiologically confirmed UTI episodes 
per patient-year (mean number of episodes per year=1.2 
vs 1.8, mean difference 0.6, 95% CI 0.0 to 1.4, p=0.02). 
Prophylaxis with trimethoprim–sulfamethoxazole also 
led to less women experiencing a microbiologically 
confirmed UTI during prophylaxis (49.4% vs 62.9%; RR 
0.79, 95% CI 0.63 to 1.0) and an increase in time to first 
UTI (6 months versus 3 months; log-rank p=0.02). There 
was no difference between arms in the mean number of 
microbiologically confirmed UTI episodes 3 months after 
cessation of prophylaxis (mean number of episodes=0.1 
vs 0.2, mean difference 0.0, 95% CI −0.1 to 0.3, p=0.64).16
Compared with vaginal oestrogen pessaries, prophylaxis 
with 100 mg of nitrofurantoin for 9 months led to fewer 
women experiencing a UTI during prophylaxis (42.3% 
vs 64.6%; RR 0.65, 95% CI 0.8 to 0.90) and a lower mean 
number of UTIs per woman (0.6 episodes per woman vs 
1.6 episodes per woman).15
Compared with D-mannose powder prophylaxis 
with 50 mg of nitrofurantoin for 6 months led to more 
postmenopausal women experiencing a UTI during 
prophylaxis (24% vs 19%, RR 1.24, 95% CI 0.57 to 2.69).14
Random effects meta-analysis (figure 2) shows long-
term antibiotic therapy reduces the risk of a woman 
experiencing a UTI during the prophylaxis period 
(pooled RR 0.76; 95% CI 0.61 to 0.95) with about eight 
post-menopausal women needing treatment with long-
term antibiotics to prevent one woman experiencing a 
Figure 1 Summary of risk of bias assessment.
Figure 2 Forest plot showing results of meta-analysis for proportion of women experiencing a UTI during the prophylaxis 
period. UTI, urinary tract infection.
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UTI during the prophylaxis period (number needed to 
treat (NNT)=8.5).
Adverse events
Commonly reported side effects across the three trials 
included skin rash, gastrointestinal disturbance and 
vaginal symptoms. There were no statistically signifi-
cant difference between risk of adverse events between 
trimethoprim–sulfamethoxazole and lactobacilli,16 or 
between nitrofurantoin and vaginal oestrogens.15 Risk 
of side effects with D-mannose powder was significantly 
lower than with nitrofurantoin (RR 0.28; 95% CI 0.13 
to 0.57).14 Overall, absolute numbers of serious adverse 
events or events resulting in treatment withdrawal were 
small.
We had data on mild adverse events (not resulting 
in treatment withdrawal) for all three trials. There was 
marked heterogeneity between trials for adverse events 
(I2=86%).
Meta-analyses showed no statistically significant differ-
ence between antibiotics and control for overall risk of 
mild adverse events (pooled RR 1.52; 95% CI 0.76 to 
3.03) (figure 3).
We extracted data for serious adverse events (resulting 
in treatment withdrawal) for two trials. Meta-analyses 
showed no statistically significant difference between 
antibiotics and control for overall risk of serious adverse 
events (pooled RR 0.90; 95% CI 0.31 to 2.66; figure 4).
effect of long-term antibiotic therapy on bacterial resistance
Compared with lactobacilli, women receiving 12 months 
prophylaxis with trimethoprim–sulfamethoxazole showed 
dramatic increases in the proportion of antibiotic resis-
tant bacteria isolated from urine and faeces. For example, 
20%–40% of urinary and faecal E coli isolates were resis-
tant to trimethoprim–sulfamethoxazole, trimethoprim 
and amoxicillin at baseline, increasing to 80%–95% 
after 1 month of treatment. Over the 15 month follow-up 
period, resistance levels decreased following cessation of 
prophylaxis but remained above baseline levels.16
sensitivity analyses
We assessed the impact of removing the study at high 
risk of bias on effect size and direction.14 Removal made 
little difference to the meta-analysis for proportion of 
women experiencing a UTI during the prophylaxis 
period (pooled RR 0.74; 95% CI 0.61 to 0.89). Removal 
did impact on the meta-analysis for proportion of women 
experiencing mild side effects during the prophylaxis 
period but overall difference between antibiotics and 
placebo did not reach statistical significance (pooled RR 
0.99, 95% CI 0.82 to 1.20).
We also pooled aggregate data from another poten-
tially relevant study where authors did not respond to 
our request for data regarding postmenopausal women/
women over 65.13 This study compared 500 mg of cran-
berry extract to 100 mg trimethoprim taken at night for 
6 months. However, adding aggregate data for the whole 
study population (women aged 45 and above) to our 
meta-analysis for the proportion of women experiencing 
a UTI during the prophylaxis period made little differ-
ence to risk estimates (pooled RR 0.74; 95% CI 0.61 to 
0.90).
dIscussIon
summary
This systematic review assessed evidence from three Euro-
pean randomised trials reported between 2003 and 2014. 
Trials only included women. Compared with controls, 
long-term prophylaxis with antibiotics reduced the risk 
of postmenopausal women experiencing a recurrent 
UTI during the prophylaxis period, without a statisti-
cally significant increase in risk of adverse events. Data 
from one trial16 suggested this benefit was limited to 
duration of prophylaxis and was not apparent 3 months 
Figure 3 Forest plot showing results of meta-analysis for proportion of women experiencing mild side effect (treatment not 
withdrawn) during the prophylaxis period.
Figure 4 Forest plot showing results of meta-analysis for proportion of women experiencing a serious side effect (resulting in 
treatment withdrawal) during the prophylaxis period.
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after cessation of prophylactic treatment. Data from one 
trial16 showed long-term antibiotic prophylaxis dramat-
ically increased urinary and faecal antibiotic resistance. 
However, trials were small with relatively short follow-up 
and had limitations in design and reporting, with one 
trial judged high risk for bias.
strengths and limitations
We conducted this review following prospective regis-
tration of a review protocol and in line with guidance 
from the Cochrane handbook for systematic reviews of 
interventions. Our search strategies was comprehen-
sive and supplemented with reviews of reference lists of 
relevant trials,13–16 systematic reviews8 17 18 and clinical 
guidelines.19–21 We contacted authors where additional 
data were required for study inclusion. Due to resource 
constraints, we limited searches to English language and 
may have missed potentially relevant studies.
comparison with existing literature
Meta-analysis of 10 randomised trials of women aged 18 
and older found long-term antibiotics reduced the risk of 
UTI recurrence during the prophylaxis period by almost 
80% (RR 0.21; 95% CI 0.13 to 0.34; NNT=1.85).8 Our 
analyses showed a smaller effect size and greater NNT for 
postmenopausal women, possibly due to more complex 
pathophysiology of recurrent UTI in this population. 
We did not identify a statistically significant increase in 
risk of adverse events associated with use of antibiotics. 
Adverse events are often poorly reported in trials,22 and 
we found heterogeneity for adverse events between trials. 
In addition, the studies included in this review compared 
long-term antibiotic therapy with various non-antibiotic 
treatments and not placebo, and this may have influ-
enced effect sizes for adverse events towards the null. We 
found small absolute numbers of serious adverse events 
and cannot exclude the possibility of important effects 
being missed in these relatively small studies.
During two point prevalence surveys, almost half of all 
adults residing in a sample of care homes were prescribed 
antibiotics for prevention of recurrent UTI.1 2 Based on 
three small trials, with relatively short follow-up periods 
and design limitations, our meta-analyses suggest that 
this widely practised use of prophylaxis reduces risk of 
recurrence in women. However, it is still unclear if these 
benefits extend to older men or frailer care home popu-
lations. These are important gaps in current evidence, 
especially given large-scale observational data showing 
10% of older men who experience an acute UTI go on to 
have at least one recurrence.23
Only one study followed up participants after cessa-
tion of prophylaxis and found that beneficial effects 
had ceased after 3 months.16 Previous studies of younger 
women have reported similar findings suggesting that 
prophylaxis only confers protection from recurrence 
during the active prophylaxis phase.8
We found little data on the impact of long-term anti-
biotic therapy on antibiotic resistance. Antibiotic use is 
associated with increased risk of resistance.3 Given the 
potential harms from acquiring an antibiotic resistant 
infection, the risk inferred by long-term antibiotic use 
is an important factor to consider with patients when 
making decisions about antibiotic prophylaxis.
Implications for research and practice
Based on the data we analysed, a pragmatic approach is 
required when considering prescribing long-term anti-
biotics in older patients with recurrent UTI. Although 
long-term antibiotics may reduce the risk of UTI recur-
rence in women, this benefit diminishes on cessation 
of treatment. Little is known about optimal prophylaxis 
period, long-term effects on health, risk of antibiotic 
resistant infections, effect in older men, effect in frail care 
home residents or impact on important patient-centred 
outcomes. These unknowns must be balanced against 
benefits and patient preferences.
Future research efforts on recurrent UTI should 
focus on improving the design and reporting of trials 
and developing a core set of outcomes to allow better 
synthesis of trial data. Antibiotic prophylaxis should 
be compared with non-antibiotic prophylaxis with 
some evidence of efficacy (such as vaginal oestrogens) 
rather than those with little or poor evidence of effi-
cacy. Researchers should address unanswered questions 
regarding long-term effects, duration of use, adverse 
effects and antibiotic resistance.
conclusIon
There is ongoing uncertainty around the benefits and 
harms of long-term antibiotics in older men and frail 
care home residents with recurrent UTI. Prescribing 
long-term antibiotics to older women with recurrent UTI 
needs careful discussion between patient and clinician 
of reduced risk of relapse, potential increases in urinary 
and faecal antibiotic resistance and rapidly diminished 
benefit once prophylaxis stops.
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